Asieris

Asieris Pharmaceuticals was founded in March 2010 as a global innovative pharmaceutical company focused on urological and reproductive system cancers and other major diseases. Adhering to the corporate mission of "Improving human health and enabling a more dignified life," Asieris is committed to becoming an internationally leading pharmaceutical enterprise integrating R&D, manufacturing, and commercialization within its specialized therapeutic areas, providing optimal integrated diagnostic and therapeutic solutions for patients in China and globally. The company upholds innovation-driven technologies and products as its core engine, building proprietary R&D platforms and core technologies to deeply explore drug mechanisms and efficiently screen and evaluate candidate drugs. Leveraging a well-established internal R&D system and extensive global drug development expertise, Asieris aims to introduce First-in-Class drugs and other innovative therapies addressing significant unmet medical needs within its focus areas. Meanwhile, through independent R&D and strategic collaborations, Asieris is strengthening its product pipeline around urological and reproductive system diseases, closely monitoring technological frontiers and treatment trends in this field, identifying unmet clinical needs, and proactively planning product portfolios and lifecycle management—from disease diagnosis to treatment—to benefit more patients in China and worldwide.